Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.58 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | AHR | P35869 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LCK | P06239 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16824896 | 0.93 | RXFP1 (0.52) | RXFP1CHRNA7MEN1KMT2ANPC1 | |
| SCHEMBL30656122 | 0.88 | RXFP1 (0.48) | RXFP1MEN1KMT2AAHRPOLB | |
| SCHEMBL16824859 | 0.88 | RXFP1 (0.48) | RXFP1MEN1KMT2AAHRPOLB | |
| SCHEMBL23298327 | 0.87 | RXFP1 (0.61) | RXFP1CHRNA7MEN1KMT2ANPC1 | |
| SCHEMBL30020399 | 0.87 | RXFP1 (0.61) | RXFP1CHRNA7MEN1KMT2ANPC1 | |
| SCHEMBL20874043 | 0.86 | RXFP1 (0.60) | RXFP1CHRNA7MEN1KMT2ANPC1 | |
| SCHEMBL28094395 | 0.85 | RXFP1 (0.46) | RXFP1CHRNA7MEN1KMT2ANPC1 | |
| SCHEMBL15206769 | 0.84 | RXFP1 (0.58) | RXFP1CHRNA7MEN1KMT2ANPC1 | |
| SCHEMBL16824895 | 0.83 | MAPT (0.67) | RXFP1MEN1KMT2ANPC1AHR | |
| SCHEMBL15206485 | 0.81 | MEN1 (0.69) | RXFP1MEN1KMT2ANPC1AHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220194947-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2022-06-23 | — | — | US | disclosed |
| US-11208413-B2 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | ALMAG DISCOVERY LIMITED (GB) | 2021-12-28 | — | — | US | disclosed |
| EP-3592745-B1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LTD (GB) | 2021-07-28 | — | — | EP | disclosed |
| US-20210128560-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2021-05-06 | — | — | US | disclosed |
| CN-110603256-A | Pyrimidopyrimidinones useful as WEE-1 kinase inhibitors | 阿尔麦克探索有限公司 | 2019-12-20 | — | — | CN | disclosed |
| US-9850247-B2 | Pyrimidopyrimidinones useful as Wee-1 kinase inhibitors | ALMAC HOUSE (GB) | 2017-12-26 | — | — | US | disclosed |
| EP-3083625-B1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LTD (GB) | 2017-11-01 | — | — | EP | disclosed |
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2016-11-03 | — | — | US | disclosed |
| EP-3083625-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | Almac Discovery Limited (GB) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015092431-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | ALMAC DISCOVERY LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11208413-B2 | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | WEE1, WEE2, NME1 | RXFP1 4036/4885CHRNA7 4827/4885MEN1 1955/4885 |
| US-20160318936-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | WEE1, WEE2, NME1 | RXFP1 4231/4885CHRNA7 4828/4885MEN1 1681/4885 |
| US-20220194947-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | WEE1, WEE2, NME1 | RXFP1 4036/4885CHRNA7 4827/4885MEN1 1955/4885 |
| US-20210128560-A1 | PYRIMIDOPYRIMIDINONES USEFUL AS WEE-1 KINASE INHIBITORS | WEE1, WEE2, NME1 | RXFP1 4036/4885CHRNA7 4827/4885MEN1 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.